Markets closed

Illumina, Inc.

ILMN · Nasdaq

Analyst Consensus

Hold

22 analysts

$208

Current

—

Low

$214

Average

—

High

Average target implies +3.03% versus the current price.

Analyst Ratings Synthesis

The supplied consensus is Hold, backed by 22 analysts, with a mean price target of $208. The low and high targets are unavailable, so target clustering and the width of the range cannot be measured. The evidence does not identify the most bullish or least bullish analyst, nor does it name any target revisions during the past week. The substantive debate visible in the supplied research is whether Illumina’s raised 2026 outlook and second-quarter beat—supported by clinical sequencing, NovaSeq X placements and consumables—can overcome the reported year-over-year profit retreat and longer-term revenue pressure. No firm-level rating distribution or revision detail is provided.

Rating Actions

No individual rating actions have been captured for ILMNyet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

B OF A GLBL RES

BAIRD R W

BARCLAYS CAPITA

CANACCORD GENUI

CITIGROUP

CO FORECST

EVERCORE ISI

GUGGENHEIM SEC.

HSBC GLOBAL RES

JP MORGAN SECUR

LEERINK PARTNRS

MORGAN STANLEY

PIPER SANDLER

RBC CAPITAL

SANFORD BERNSTE

SCOTIABANK

STEPHENS INC

STIFEL NICOLAUS

TD COWEN

UBS

WOLFE RESEARCH

ZACKS RESEARCH

Symbol: ILMN
Type: Stock
Sector: Health Care
Industry: Laboratory Analytical Instruments
Exchange: Nasdaq

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.

Key Issues

Bullish view

Illumina raised its 2026 revenue and earnings outlook after second-quarter results exceeded expectations, indicating that management sees demand and execution improving. Clinical sequencing, NovaSeq X placements and consumables each supported the stronger outlook.

Bearish view

Second-quarter profit still declined year over year, and the stock remains near a 52-week high according to Zacks. The higher outlook therefore needs to translate into sustained earnings growth rather than a one-quarter beat.

Analyst Consensus

See all

Hold

22 analysts

$208

Current

—

Low

$214

Average

—

High

Average target implies +3.03% versus the current price.

Earnings History

BeatMissNo estimate

Illumina, Inc.

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers